Loading clinical trials...
Loading clinical trials...
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma That Aim to Achieve and Maintain Measurable Residual Disease (MRD)-Negativity in Community Oncology Settings
Conditions
Interventions
Multiple Myeloma Pathway
All4Cure Platform
+1 more
Locations
1
United States
All4Cure
Seattle, Washington, United States
Start Date
April 18, 2024
Primary Completion Date
May 31, 2026
Completion Date
December 1, 2026
Last Updated
May 3, 2024
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
All4Cure
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions